Parodis I - Search Results

1

Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus.

Parodis I, Johansson P, Gomez A, Soukka S, Emamikia S, Chatzidionysiou K. Parodis I, et al. Rheumatology (Oxford). 2019 Dec 1;58(12):2170-2176. doi: 10.1093/rheumatology/kez191. Rheumatology (Oxford). 2019. PMID: 31157891 Free PMC article.

2

Belimumab for systemic lupus erythematosus: a practice-based view.

Parodis I, Axelsson M, Gunnarsson I. Parodis I, et al. Lupus. 2013 Apr;22(4):372-80. doi: 10.1177/0961203313476154. Lupus. 2013. PMID: 23553780

3

Biologics in SLE: towards new approaches.

van Vollenhoven RF, Parodis I, Levitsky A. van Vollenhoven RF, et al. Among authors: parodis i. Best Pract Res Clin Rheumatol. 2013 Jun;27(3):341-9. doi: 10.1016/j.berh.2013.07.006. Best Pract Res Clin Rheumatol. 2013. PMID: 24238691 Review.

4

Antiphospholipid Antibodies in Lupus Nephritis.

Parodis I, Arnaud L, Gerhardsson J, Zickert A, Sundelin B, Malmström V, Svenungsson E, Gunnarsson I. Parodis I, et al. PLoS One. 2016 Jun 23;11(6):e0158076. doi: 10.1371/journal.pone.0158076. eCollection 2016. PLoS One. 2016. PMID: 27336701 Free PMC article.

5

Serum soluble tumour necrosis factor receptor-2 (sTNFR2) as a biomarker of kidney tissue damage and long-term renal outcome in lupus nephritis.

Parodis I, Ding H, Zickert A, Arnaud L, Larsson A, Svenungsson E, Mohan C, Gunnarsson I. Parodis I, et al. Scand J Rheumatol. 2017 Jul;46(4):263-272. doi: 10.1080/03009742.2016.1231339. Epub 2016 Dec 15. Scand J Rheumatol. 2017. PMID: 27973968 Free PMC article.

6

Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus.

Parodis I, Sjöwall C, Jönsen A, Ramsköld D, Zickert A, Frodlund M, Sohrabian A, Arnaud L, Rönnelid J, Malmström V, Bengtsson AA, Gunnarsson I. Parodis I, et al. Autoimmun Rev. 2017 Apr;16(4):343-351. doi: 10.1016/j.autrev.2017.02.005. Epub 2017 Feb 13. Autoimmun Rev. 2017. PMID: 28216072 Review.

7

Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus - distinct roles of BAFF and APRIL.

Parodis I, Söder F, Faustini F, Kasza Z, Samuelsson I, Zickert A, Svenungsson E, van Vollenhoven RF, Malmström V, Wermeling F, Gunnarsson I. Parodis I, et al. Lupus. 2018 Aug;27(9):1470-1478. doi: 10.1177/0961203318777116. Epub 2018 May 21. Lupus. 2018. PMID: 29783918

8

Smoking reduces the efficacy of belimumab in mucocutaneous lupus.

Parodis I, Gomez A, Frodlund M, Jönsen A, Zickert A, Sjöwall C, Bengtsson AA, Gunnarsson I. Parodis I, et al. Expert Opin Biol Ther. 2018 Aug;18(8):911-920. doi: 10.1080/14712598.2018.1494719. Epub 2018 Jul 9. Expert Opin Biol Ther. 2018. PMID: 29958508 Free article.

9

The Impact of Belimumab and Rituximab on Health-Related Quality of Life in Patients With Systemic Lupus Erythematosus.

Parodis I, Lopez Benavides AH, Zickert A, Pettersson S, Möller S, Welin Henriksson E, Voss A, Gunnarsson I. Parodis I, et al. Arthritis Care Res (Hoboken). 2019 Jun;71(6):811-821. doi: 10.1002/acr.23718. Arthritis Care Res (Hoboken). 2019. PMID: 30055091

10

Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies.

Parodis I, Emamikia S, Gomez A, Gunnarsson I, van Vollenhoven RF, Chatzidionysiou K. Parodis I, et al. Expert Opin Biol Ther. 2019 Feb;19(2):157-168. doi: 10.1080/14712598.2019.1561856. Epub 2018 Dec 27. Expert Opin Biol Ther. 2019. PMID: 30571926 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

130 results

Search Page